Compare Suzuken Co., Ltd. with Similar Stocks
Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Poor long term growth as Net Sales has grown by an annual rate of 1.63% over the last 5 years
3
Flat results in Dec 25
4
With ROE of 9.07%, it has a very attractive valuation with a 1.01 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 451,911 Million (Mid Cap)
11.00
NA
0.00%
-0.37
8.09%
1.11
Revenue and Profits:
Net Sales:
666,190 Million
(Quarterly Results - Dec 2025)
Net Profit:
14,776 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.75%
0%
-5.75%
6 Months
0.85%
0%
0.85%
1 Year
14.95%
0%
14.95%
2 Years
25.91%
0%
25.91%
3 Years
78.2%
0%
78.2%
4 Years
54.8%
0%
54.8%
5 Years
31.15%
0%
31.15%
Suzuken Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.63%
EBIT Growth (5y)
2.67%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
5.76
Tax Ratio
31.39%
Dividend Payout Ratio
22.00%
Pledged Shares
0
Institutional Holding
0.39%
ROCE (avg)
11.93%
ROE (avg)
5.93%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.01
EV to EBIT
7.21
EV to EBITDA
5.45
EV to Capital Employed
1.01
EV to Sales
0.11
PEG Ratio
0.51
Dividend Yield
NA
ROCE (Latest)
13.97%
ROE (Latest)
9.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bullish
Shareholding Snapshot : Sep 2018
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
666,190.00
641,347.00
3.87%
Operating Profit (PBDIT) excl Other Income
13,532.00
15,783.00
-14.26%
Interest
11.00
10.00
10.00%
Exceptional Items
108.00
231.00
-53.25%
Consolidate Net Profit
14,776.00
10,395.00
42.15%
Operating Profit Margin (Excl OI)
15.40%
19.80%
-0.44%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 3.87% vs 3.47% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 42.15% vs 8.17% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
2,399,952.00
2,386,493.00
0.56%
Operating Profit (PBDIT) excl Other Income
49,189.00
43,620.00
12.77%
Interest
41.00
43.00
-4.65%
Exceptional Items
-2,306.00
-2,391.00
3.55%
Consolidate Net Profit
34,503.00
29,000.00
18.98%
Operating Profit Margin (Excl OI)
15.50%
14.60%
0.09%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 0.56% vs 3.10% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 18.98% vs 42.72% in Mar 2024
About Suzuken Co., Ltd. 
Suzuken Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






